brinsupri insmed - Search News

News

Insmed’s lung disease drug approved in U.S.

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis.

Pharmaceutical Technology on M… · 2d

Insmed wins FDA approval for future blockbuster Brinsupri

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (DPP1) inhibitor and the first therapy for non-cystic fibrosis bronchiectasis (NCFB) approved by the US Food and Drug Administration (FDA).

Reuters on MSN · 2d

US FDA approves Insmed's drug as first treatment for a chronic lung disease

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.

Stocktwits on MSN2d

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

PharmExec3d

FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

Medical Dialogues5h

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a ...

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Asianet Newsable on MSN2d

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic

Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.

TipRanks on MSN3d

Hide inaccessible results

News

Insmed’s lung disease drug approved in U.S.

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic

Brinsupri approval sets stage for next leg of Insmed growth, says BofA

VytlOne Announces New Partnership with Insmed

Insmed price target raised to $138 from $120 at RBC Capital

Related topics